Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.

Archives of gynecology and obstetrics - 1 Jun 2021

Raffone Antonio, Travaglino Antonio, Gabrielli Olimpia, Micheli Mariacarolina, Zuccalà Valeria, Bitonti Giovanna, Camastra Caterina, Gargiulo Valentina, Insabato Luigi, Zullo Fulvio

Abstract excerpt

BACKGROUND: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Genes, p53

Share to Poly-ADP-Ribose Binding Proteins

Share to PTEN Phosphohydrolase

Share to Risk Assessment

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 33754186
DOI: 10.1007/s00404-021-06028-4
PMCID: PMC8087601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.PMID 33754186Read ↗

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Semantic proximity Read ↗

Association of Molecular Classification with FIGO Stage and Survival Outcomes in Endometrial Cancer.Semantic proximity Read ↗

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancerSemantic proximity Read ↗

Implementation of the ProMisE classifier and validation of its prognostic impact in Brazilian endometrial carcinomasSemantic proximity Read ↗

Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols.Semantic proximity Read ↗

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.Semantic proximity Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.Semantic proximity Read ↗

Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Semantic proximity Read ↗

Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.Semantic proximity Read ↗

Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.Semantic proximity Read ↗

Analysis of Differences in the Classification of Endometrial Cancer Patients in PolandSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.